http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 11 Aug 2026 09:18:15 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/New+Coverage/Craig-Hallum+Starts+Alterity+Therapeutics+%28ATHE%29+at+Buy/26901359.html (Updated - August 11, 2026 9:18 AM EDT) <p>Craig-Hallum analyst Adam Vogel initiates coverage on Alterity Therapeutics (NASDAQ: ATHE) with a Buy rating and a price target of $12.00.</p><p>The analyst comments "We view ATH434 as a high-risk but unusually asymmetric multiple system atrophy (MSA) pivotal story with substantial upside if Ph3 confirms the Ph2 signal. ATHE's current valuation appears to reflect financing, replication, and small-company execution risk while assigning limited value to an oral asset with randomized 12-mo functional data and a written FDA-confirmed registrational path. At current levels, the thesis does not require ATH434 to be de-risked; it requires recognizing http://www.streetinsider.com/New+Coverage/Craig-Hallum+Starts+Alterity+Therapeutics+%28ATHE%29+at+Buy/26901359.html Tue, 11 Aug 2026 09:18:15 -0400 ATHE http://www.streetinsider.com/Analyst+Comments/Craig-Hallum+Starts+Alterity+Therapeutics+%28ATHE%29+at+Buy/26901359.html (Updated - August 11, 2026 9:18 AM EDT) <p>Craig-Hallum analyst Adam Vogel initiates coverage on Alterity Therapeutics (NASDAQ: ATHE) with a Buy rating and a price target of $12.00.</p><p>The analyst comments "We view ATH434 as a high-risk but unusually asymmetric multiple system atrophy (MSA) pivotal story with substantial upside if Ph3 confirms the Ph2 signal. ATHE's current valuation appears to reflect financing, replication, and small-company execution risk while assigning limited value to an oral asset with randomized 12-mo functional data and a written FDA-confirmed registrational path. At current levels, the thesis does not require ATH434 to be de-risked; it requires recognizing http://www.streetinsider.com/Analyst+Comments/Craig-Hallum+Starts+Alterity+Therapeutics+%28ATHE%29+at+Buy/26901359.html Tue, 11 Aug 2026 09:18:15 -0400 ATHE http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html <p align="justify"><strong>Highlights</strong></p> <ul type="disc"><li style="margin-bottom:5pt;">FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)</li><li style="margin-bottom:5pt;">FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA</li><li style="margin-bottom:5pt;">Pivotal Phase 3 trial activities on track to initiate by year-end 2026</li><li style="margin-bottom:5pt;">Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value</li><li style="margin-bottom:5pt;">Peer-reviewed publication in <em>NeuroImage</em> validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA</li><li style="margin-bottom:5pt;">Strengthened the Board of Directors with the http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html Thu, 30 Jul 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.35954321 A.60012014 ATH ATH.AX ATHE O.00573636 O.00730626 O.01951358 O.20026344 O.20737027 O.29757805 http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html <p align="justify"><strong>Highlights</strong></p> <ul type="disc"><li style="margin-bottom:5pt;">FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)</li><li style="margin-bottom:5pt;">FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA</li><li style="margin-bottom:5pt;">Pivotal Phase 3 trial activities on track to initiate by year-end 2026</li><li style="margin-bottom:5pt;">Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value</li><li style="margin-bottom:5pt;">Peer-reviewed publication in <em>NeuroImage</em> validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA</li><li style="margin-bottom:5pt;">Strengthened the Board of Directors with the http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html Thu, 30 Jul 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.35954321 A.60012014 ATH ATH.AX ATHE O.00573636 O.00730626 O.01951358 O.20026344 O.20737027 O.29757805 http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html <p align="justify"><strong>Highlights</strong></p> <ul type="disc"><li style="margin-bottom:5pt;">FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)</li><li style="margin-bottom:5pt;">FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA</li><li style="margin-bottom:5pt;">Pivotal Phase 3 trial activities on track to initiate by year-end 2026</li><li style="margin-bottom:5pt;">Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value</li><li style="margin-bottom:5pt;">Peer-reviewed publication in <em>NeuroImage</em> validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA</li><li style="margin-bottom:5pt;">Strengthened the Board of Directors with the http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html Thu, 30 Jul 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.35954321 A.60012014 ATH ATH.AX ATHE O.00573636 O.00730626 O.01951358 O.20026344 O.20737027 O.29757805 http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html <p align="justify"><strong>Highlights</strong></p> <ul type="disc"><li style="margin-bottom:5pt;">FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)</li><li style="margin-bottom:5pt;">FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA</li><li style="margin-bottom:5pt;">Pivotal Phase 3 trial activities on track to initiate by year-end 2026</li><li style="margin-bottom:5pt;">Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value</li><li style="margin-bottom:5pt;">Peer-reviewed publication in <em>NeuroImage</em> validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA</li><li style="margin-bottom:5pt;">Strengthened the Board of Directors with the http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html Thu, 30 Jul 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.35954321 A.60012014 ATH ATH.AX ATHE O.00573636 O.00730626 O.01951358 O.20026344 O.20737027 O.29757805 http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html <p align="justify"><strong>Highlights</strong></p> <ul type="disc"><li style="margin-bottom:5pt;">FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)</li><li style="margin-bottom:5pt;">FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA</li><li style="margin-bottom:5pt;">Pivotal Phase 3 trial activities on track to initiate by year-end 2026</li><li style="margin-bottom:5pt;">Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value</li><li style="margin-bottom:5pt;">Peer-reviewed publication in <em>NeuroImage</em> validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA</li><li style="margin-bottom:5pt;">Strengthened the Board of Directors with the http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html Thu, 30 Jul 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.35954321 A.60012014 ATH ATH.AX ATHE O.00573636 O.00730626 O.01951358 O.20026344 O.20737027 O.29757805 http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html <p align="justify"><strong>Highlights</strong></p> <ul type="disc"><li style="margin-bottom:5pt;">FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)</li><li style="margin-bottom:5pt;">FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA</li><li style="margin-bottom:5pt;">Pivotal Phase 3 trial activities on track to initiate by year-end 2026</li><li style="margin-bottom:5pt;">Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value</li><li style="margin-bottom:5pt;">Peer-reviewed publication in <em>NeuroImage</em> validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA</li><li style="margin-bottom:5pt;">Strengthened the Board of Directors with the http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html Thu, 30 Jul 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.35954321 A.60012014 ATH ATH.AX ATHE O.00573636 O.00730626 O.01951358 O.20026344 O.20737027 O.29757805 http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html <p align="justify"><strong>Highlights</strong></p> <ul type="disc"><li style="margin-bottom:5pt;">FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)</li><li style="margin-bottom:5pt;">FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA</li><li style="margin-bottom:5pt;">Pivotal Phase 3 trial activities on track to initiate by year-end 2026</li><li style="margin-bottom:5pt;">Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value</li><li style="margin-bottom:5pt;">Peer-reviewed publication in <em>NeuroImage</em> validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA</li><li style="margin-bottom:5pt;">Strengthened the Board of Directors with the http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html Thu, 30 Jul 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.35954321 A.60012014 ATH ATH.AX ATHE O.00573636 O.00730626 O.01951358 O.20026344 O.20737027 O.29757805 http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html <p align="justify"><strong>Highlights</strong></p> <ul type="disc"><li style="margin-bottom:5pt;">FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)</li><li style="margin-bottom:5pt;">FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA</li><li style="margin-bottom:5pt;">Pivotal Phase 3 trial activities on track to initiate by year-end 2026</li><li style="margin-bottom:5pt;">Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value</li><li style="margin-bottom:5pt;">Peer-reviewed publication in <em>NeuroImage</em> validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA</li><li style="margin-bottom:5pt;">Strengthened the Board of Directors with the http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html Thu, 30 Jul 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.35954321 A.60012014 ATH ATH.AX ATHE O.00573636 O.00730626 O.01951358 O.20026344 O.20737027 O.29757805 http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html <p align="justify"><strong>Highlights</strong></p> <ul type="disc"><li style="margin-bottom:5pt;">FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)</li><li style="margin-bottom:5pt;">FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA</li><li style="margin-bottom:5pt;">Pivotal Phase 3 trial activities on track to initiate by year-end 2026</li><li style="margin-bottom:5pt;">Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value</li><li style="margin-bottom:5pt;">Peer-reviewed publication in <em>NeuroImage</em> validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA</li><li style="margin-bottom:5pt;">Strengthened the Board of Directors with the http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html Thu, 30 Jul 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.35954321 A.60012014 ATH ATH.AX ATHE O.00573636 O.00730626 O.01951358 O.20026344 O.20737027 O.29757805 http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html <p align="justify"><strong>Highlights</strong></p> <ul type="disc"><li style="margin-bottom:5pt;">FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)</li><li style="margin-bottom:5pt;">FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA</li><li style="margin-bottom:5pt;">Pivotal Phase 3 trial activities on track to initiate by year-end 2026</li><li style="margin-bottom:5pt;">Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value</li><li style="margin-bottom:5pt;">Peer-reviewed publication in <em>NeuroImage</em> validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA</li><li style="margin-bottom:5pt;">Strengthened the Board of Directors with the http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html Thu, 30 Jul 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.35954321 A.60012014 ATH ATH.AX ATHE O.00573636 O.00730626 O.01951358 O.20026344 O.20737027 O.29757805 http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html <p align="justify"><strong>Highlights</strong></p> <ul type="disc"><li style="margin-bottom:5pt;">FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)</li><li style="margin-bottom:5pt;">FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA</li><li style="margin-bottom:5pt;">Pivotal Phase 3 trial activities on track to initiate by year-end 2026</li><li style="margin-bottom:5pt;">Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value</li><li style="margin-bottom:5pt;">Peer-reviewed publication in <em>NeuroImage</em> validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA</li><li style="margin-bottom:5pt;">Strengthened the Board of Directors with the http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html Thu, 30 Jul 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.35954321 A.60012014 ATH ATH.AX ATHE O.00573636 O.00730626 O.01951358 O.20026344 O.20737027 O.29757805 http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html <p align="justify"><strong>Highlights</strong></p> <ul type="disc"><li style="margin-bottom:5pt;">FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)</li><li style="margin-bottom:5pt;">FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA</li><li style="margin-bottom:5pt;">Pivotal Phase 3 trial activities on track to initiate by year-end 2026</li><li style="margin-bottom:5pt;">Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value</li><li style="margin-bottom:5pt;">Peer-reviewed publication in <em>NeuroImage</em> validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA</li><li style="margin-bottom:5pt;">Strengthened the Board of Directors with the http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html Thu, 30 Jul 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.35954321 A.60012014 ATH ATH.AX ATHE O.00573636 O.00730626 O.01951358 O.20026344 O.20737027 O.29757805 http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html <p align="justify"><strong>Highlights</strong></p> <ul type="disc"><li style="margin-bottom:5pt;">FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)</li><li style="margin-bottom:5pt;">FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA</li><li style="margin-bottom:5pt;">Pivotal Phase 3 trial activities on track to initiate by year-end 2026</li><li style="margin-bottom:5pt;">Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value</li><li style="margin-bottom:5pt;">Peer-reviewed publication in <em>NeuroImage</em> validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA</li><li style="margin-bottom:5pt;">Strengthened the Board of Directors with the http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html Thu, 30 Jul 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.35954321 A.60012014 ATH ATH.AX ATHE O.00573636 O.00730626 O.01951358 O.20026344 O.20737027 O.29757805 http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html <p align="justify"><strong>Highlights</strong></p> <ul type="disc"><li style="margin-bottom:5pt;">FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)</li><li style="margin-bottom:5pt;">FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA</li><li style="margin-bottom:5pt;">Pivotal Phase 3 trial activities on track to initiate by year-end 2026</li><li style="margin-bottom:5pt;">Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value</li><li style="margin-bottom:5pt;">Peer-reviewed publication in <em>NeuroImage</em> validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA</li><li style="margin-bottom:5pt;">Strengthened the Board of Directors with the http://www.streetinsider.com/Press+Releases/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html Thu, 30 Jul 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.35954321 A.60012014 ATH ATH.AX ATHE O.00573636 O.00730626 O.01951358 O.20026344 O.20737027 O.29757805 http://www.streetinsider.com/Globe+Newswire/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html <p align="justify"><strong>Highlights</strong></p> <ul type="disc"><li style="margin-bottom:5pt;">FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)</li><li style="margin-bottom:5pt;">FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA</li><li style="margin-bottom:5pt;">Pivotal Phase 3 trial activities on track to initiate by year-end 2026</li><li style="margin-bottom:5pt;">Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value</li><li style="margin-bottom:5pt;">Peer-reviewed publication in <em>NeuroImage</em> validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA</li><li style="margin-bottom:5pt;">Strengthened the Board of Directors with the http://www.streetinsider.com/Globe+Newswire/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html Thu, 30 Jul 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.35954321 A.60012014 ATH ATH.AX ATHE O.00573636 O.00730626 O.01951358 O.20026344 O.20737027 O.29757805 http://www.streetinsider.com/Globe+Newswire/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html <p align="justify"><strong>Highlights</strong></p> <ul type="disc"><li style="margin-bottom:5pt;">FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)</li><li style="margin-bottom:5pt;">FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA</li><li style="margin-bottom:5pt;">Pivotal Phase 3 trial activities on track to initiate by year-end 2026</li><li style="margin-bottom:5pt;">Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value</li><li style="margin-bottom:5pt;">Peer-reviewed publication in <em>NeuroImage</em> validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA</li><li style="margin-bottom:5pt;">Strengthened the Board of Directors with the http://www.streetinsider.com/Globe+Newswire/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html Thu, 30 Jul 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.35954321 A.60012014 ATH ATH.AX ATHE O.00573636 O.00730626 O.01951358 O.20026344 O.20737027 O.29757805 http://www.streetinsider.com/Globe+Newswire/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html <p align="justify"><strong>Highlights</strong></p> <ul type="disc"><li style="margin-bottom:5pt;">FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)</li><li style="margin-bottom:5pt;">FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA</li><li style="margin-bottom:5pt;">Pivotal Phase 3 trial activities on track to initiate by year-end 2026</li><li style="margin-bottom:5pt;">Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value</li><li style="margin-bottom:5pt;">Peer-reviewed publication in <em>NeuroImage</em> validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA</li><li style="margin-bottom:5pt;">Strengthened the Board of Directors with the http://www.streetinsider.com/Globe+Newswire/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html Thu, 30 Jul 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.35954321 A.60012014 ATH ATH.AX ATHE O.00573636 O.00730626 O.01951358 O.20026344 O.20737027 O.29757805 http://www.streetinsider.com/Globe+Newswire/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html <p align="justify"><strong>Highlights</strong></p> <ul type="disc"><li style="margin-bottom:5pt;">FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)</li><li style="margin-bottom:5pt;">FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA</li><li style="margin-bottom:5pt;">Pivotal Phase 3 trial activities on track to initiate by year-end 2026</li><li style="margin-bottom:5pt;">Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value</li><li style="margin-bottom:5pt;">Peer-reviewed publication in <em>NeuroImage</em> validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA</li><li style="margin-bottom:5pt;">Strengthened the Board of Directors with the http://www.streetinsider.com/Globe+Newswire/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html Thu, 30 Jul 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.35954321 A.60012014 ATH ATH.AX ATHE O.00573636 O.00730626 O.01951358 O.20026344 O.20737027 O.29757805 http://www.streetinsider.com/Globe+Newswire/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html <p align="justify"><strong>Highlights</strong></p> <ul type="disc"><li style="margin-bottom:5pt;">FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)</li><li style="margin-bottom:5pt;">FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA</li><li style="margin-bottom:5pt;">Pivotal Phase 3 trial activities on track to initiate by year-end 2026</li><li style="margin-bottom:5pt;">Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value</li><li style="margin-bottom:5pt;">Peer-reviewed publication in <em>NeuroImage</em> validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA</li><li style="margin-bottom:5pt;">Strengthened the Board of Directors with the http://www.streetinsider.com/Globe+Newswire/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html Thu, 30 Jul 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.35954321 A.60012014 ATH ATH.AX ATHE O.00573636 O.00730626 O.01951358 O.20026344 O.20737027 O.29757805 http://www.streetinsider.com/Globe+Newswire/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html <p align="justify"><strong>Highlights</strong></p> <ul type="disc"><li style="margin-bottom:5pt;">FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)</li><li style="margin-bottom:5pt;">FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA</li><li style="margin-bottom:5pt;">Pivotal Phase 3 trial activities on track to initiate by year-end 2026</li><li style="margin-bottom:5pt;">Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value</li><li style="margin-bottom:5pt;">Peer-reviewed publication in <em>NeuroImage</em> validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA</li><li style="margin-bottom:5pt;">Strengthened the Board of Directors with the http://www.streetinsider.com/Globe+Newswire/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html Thu, 30 Jul 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.35954321 A.60012014 ATH ATH.AX ATHE O.00573636 O.00730626 O.01951358 O.20026344 O.20737027 O.29757805 http://www.streetinsider.com/Globe+Newswire/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html <p align="justify"><strong>Highlights</strong></p> <ul type="disc"><li style="margin-bottom:5pt;">FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)</li><li style="margin-bottom:5pt;">FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA</li><li style="margin-bottom:5pt;">Pivotal Phase 3 trial activities on track to initiate by year-end 2026</li><li style="margin-bottom:5pt;">Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value</li><li style="margin-bottom:5pt;">Peer-reviewed publication in <em>NeuroImage</em> validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA</li><li style="margin-bottom:5pt;">Strengthened the Board of Directors with the http://www.streetinsider.com/Globe+Newswire/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html Thu, 30 Jul 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.35954321 A.60012014 ATH ATH.AX ATHE O.00573636 O.00730626 O.01951358 O.20026344 O.20737027 O.29757805 http://www.streetinsider.com/Globe+Newswire/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html <p align="justify"><strong>Highlights</strong></p> <ul type="disc"><li style="margin-bottom:5pt;">FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)</li><li style="margin-bottom:5pt;">FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA</li><li style="margin-bottom:5pt;">Pivotal Phase 3 trial activities on track to initiate by year-end 2026</li><li style="margin-bottom:5pt;">Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value</li><li style="margin-bottom:5pt;">Peer-reviewed publication in <em>NeuroImage</em> validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA</li><li style="margin-bottom:5pt;">Strengthened the Board of Directors with the http://www.streetinsider.com/Globe+Newswire/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html Thu, 30 Jul 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.35954321 A.60012014 ATH ATH.AX ATHE O.00573636 O.00730626 O.01951358 O.20026344 O.20737027 O.29757805 http://www.streetinsider.com/Globe+Newswire/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html <p align="justify"><strong>Highlights</strong></p> <ul type="disc"><li style="margin-bottom:5pt;">FDA End-of-Phase 2 (EOP2) meeting minutes confirmed a registrational pathway for ATH434 in Multiple System Atrophy (MSA)</li><li style="margin-bottom:5pt;">FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA</li><li style="margin-bottom:5pt;">Pivotal Phase 3 trial activities on track to initiate by year-end 2026</li><li style="margin-bottom:5pt;">Continued evaluation of strategic funding and partnering alternatives to support Phase 3 development and maximise long-term shareholder value</li><li style="margin-bottom:5pt;">Peer-reviewed publication in <em>NeuroImage</em> validated quantitative susceptibility mapping (QSM) of iron on MRI as a biomarker of MSA</li><li style="margin-bottom:5pt;">Strengthened the Board of Directors with the http://www.streetinsider.com/Globe+Newswire/Alterity+Therapeutics+Releases+Appendix+4C+%E2%80%93+Q4+FY26+Quarterly+Cash+Flow+Report+%26amp%3B+Corporate+Update/26838742.html Thu, 30 Jul 2026 07:25:00 -0400 A.06822034 A.19718279 A.31293549 A.35954321 A.60012014 ATH ATH.AX ATHE O.00573636 O.00730626 O.01951358 O.20026344 O.20737027 O.29757805